|
|||||
|
|

Pet insurance provider Trupanion (NASDAQ:TRUP) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 11.7% year on year to $376.9 million. Its GAAP profit of $0.13 per share was 20.1% below analysts’ consensus estimates.
Is now the time to buy TRUP? Find out in our full research report (it’s free for active Edge members).
Trupanion’s fourth quarter was shaped by a combination of higher retention rates and stepped-up pet acquisition efforts, resulting in notable gains in subscription revenue and adjusted operating income. Management credited improved pricing alignment and operational efficiencies for the margin expansion achieved during the quarter. CEO Margaret Tooth highlighted, “Retention is a key driver of long-term growth in adjusted operating income, and that commitment paid off in 2025 with trailing twelve-month retention improving in every single quarter.” The quarter also benefited from increased brand investment, which management said accelerated new pet signups and contributed to the 8% year-over-year rise in gross pet additions.
Looking ahead, Trupanion’s guidance is underpinned by a continued focus on disciplined pricing, expense management, and expansion of its member base both domestically and internationally. Management expects pricing to remain the primary driver of revenue growth in the near term, but notes that new pet acquisition is expected to play a larger role over time. CFO Fawwad Qureshi cautioned, “We have not seen a significant abatement of inflation. Obviously, it is something we look at pretty carefully,” signaling that veterinary cost trends remain a key variable in the outlook. Product enhancements and targeted brand spending are expected to further support growth and retention initiatives.
Management attributed the quarter’s results to improved retention, higher-margin pet cohorts, and increased investments in brand awareness and pet acquisition.
Trupanion’s forward outlook is built on disciplined pricing, operational efficiency, and expansion of its product and market footprint.
Over the next few quarters, the StockStory team will monitor (1) the impact of brand and marketing investments on gross pet additions and retention rates, (2) the launch and early traction of new product initiatives like Landspath and potential lower-priced plans, and (3) the company’s ability to maintain or expand adjusted operating margins despite persistent veterinary inflation. Additionally, the evolution of competitive dynamics in the pet insurance market and international expansion progress will be areas of ongoing focus.
Trupanion currently trades at $32.14, in line with $32.14 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
| Feb-13 | |
| Feb-13 | |
| Feb-13 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Feb-11 | |
| Feb-10 | |
| Feb-06 | |
| Feb-05 | |
| Feb-04 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite